Cargando…

The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study

Background. The aim of this study was to validate the impact of type 2 diabetes (T2D) on the platelet reactivity in patients with acute ST elevation myocardial infarction (STEMI) treated with adenosine diphosphate (ADP) receptor blockers. Methods. A pilot prospective study was performed. Totally 67...

Descripción completa

Detalles Bibliográficos
Autores principales: Samoš, Matej, Fedor, Marián, Kovář, František, Galajda, Peter, Bolek, Tomáš, Stančiaková, Lucia, Fedorová, Jana, Staško, Ján, Kubisz, Peter, Mokáň, Marián
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967473/
https://www.ncbi.nlm.nih.gov/pubmed/27493970
http://dx.doi.org/10.1155/2016/2909436
_version_ 1782445521797906432
author Samoš, Matej
Fedor, Marián
Kovář, František
Galajda, Peter
Bolek, Tomáš
Stančiaková, Lucia
Fedorová, Jana
Staško, Ján
Kubisz, Peter
Mokáň, Marián
author_facet Samoš, Matej
Fedor, Marián
Kovář, František
Galajda, Peter
Bolek, Tomáš
Stančiaková, Lucia
Fedorová, Jana
Staško, Ján
Kubisz, Peter
Mokáň, Marián
author_sort Samoš, Matej
collection PubMed
description Background. The aim of this study was to validate the impact of type 2 diabetes (T2D) on the platelet reactivity in patients with acute ST elevation myocardial infarction (STEMI) treated with adenosine diphosphate (ADP) receptor blockers. Methods. A pilot prospective study was performed. Totally 67 patients were enrolled. 21 patients had T2D. Among all study population, 33 patients received clopidogrel and 34 patients received prasugrel. The efficacy of ADP receptor blocker therapy had been tested in two time intervals using light transmission aggregometry with specific inducer and vasodilator-stimulated phosphoprotein phosphorylation (VASP-P) flow cytometry assay. Results. There were no significant differences in platelet aggregability among T2D and nondiabetic (ND) group. The platelet reactivity index of VASP-P did not differ significantly between T2D and ND group (59.4 ± 30.9% versus 60.0 ± 25.2% and 33.9 ± 25.3% versus 38.6 ± 29.3% in second testing). The number of ADP receptor blocker nonresponders did not differ significantly between T2D and ND patients. The time interval from ADP receptor blocker loading dosing to the blood sampling was similar in T2D and ND patients in both examinations. Conclusion. This prospective study did not confirm the higher platelet reactivity and higher prevalence of ADP receptor blocker nonresponders in T2D acute STEMI patients.
format Online
Article
Text
id pubmed-4967473
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-49674732016-08-04 The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study Samoš, Matej Fedor, Marián Kovář, František Galajda, Peter Bolek, Tomáš Stančiaková, Lucia Fedorová, Jana Staško, Ján Kubisz, Peter Mokáň, Marián J Diabetes Res Research Article Background. The aim of this study was to validate the impact of type 2 diabetes (T2D) on the platelet reactivity in patients with acute ST elevation myocardial infarction (STEMI) treated with adenosine diphosphate (ADP) receptor blockers. Methods. A pilot prospective study was performed. Totally 67 patients were enrolled. 21 patients had T2D. Among all study population, 33 patients received clopidogrel and 34 patients received prasugrel. The efficacy of ADP receptor blocker therapy had been tested in two time intervals using light transmission aggregometry with specific inducer and vasodilator-stimulated phosphoprotein phosphorylation (VASP-P) flow cytometry assay. Results. There were no significant differences in platelet aggregability among T2D and nondiabetic (ND) group. The platelet reactivity index of VASP-P did not differ significantly between T2D and ND group (59.4 ± 30.9% versus 60.0 ± 25.2% and 33.9 ± 25.3% versus 38.6 ± 29.3% in second testing). The number of ADP receptor blocker nonresponders did not differ significantly between T2D and ND patients. The time interval from ADP receptor blocker loading dosing to the blood sampling was similar in T2D and ND patients in both examinations. Conclusion. This prospective study did not confirm the higher platelet reactivity and higher prevalence of ADP receptor blocker nonresponders in T2D acute STEMI patients. Hindawi Publishing Corporation 2016 2016-07-17 /pmc/articles/PMC4967473/ /pubmed/27493970 http://dx.doi.org/10.1155/2016/2909436 Text en Copyright © 2016 Matej Samoš et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Samoš, Matej
Fedor, Marián
Kovář, František
Galajda, Peter
Bolek, Tomáš
Stančiaková, Lucia
Fedorová, Jana
Staško, Ján
Kubisz, Peter
Mokáň, Marián
The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study
title The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study
title_full The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study
title_fullStr The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study
title_full_unstemmed The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study
title_short The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study
title_sort impact of type 2 diabetes on the efficacy of adp receptor blockers in patients with acute st elevation myocardial infarction: a pilot prospective study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967473/
https://www.ncbi.nlm.nih.gov/pubmed/27493970
http://dx.doi.org/10.1155/2016/2909436
work_keys_str_mv AT samosmatej theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy
AT fedormarian theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy
AT kovarfrantisek theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy
AT galajdapeter theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy
AT bolektomas theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy
AT stanciakovalucia theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy
AT fedorovajana theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy
AT staskojan theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy
AT kubiszpeter theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy
AT mokanmarian theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy
AT samosmatej impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy
AT fedormarian impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy
AT kovarfrantisek impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy
AT galajdapeter impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy
AT bolektomas impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy
AT stanciakovalucia impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy
AT fedorovajana impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy
AT staskojan impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy
AT kubiszpeter impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy
AT mokanmarian impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy